AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+27.87%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.4B
AUM Growth
+$2.4B
(+17%)
Cap. Flow
-$4.25M
Cap. Flow
% of AUM
-0.18%
Top 10 Holdings %
Top 10 Hldgs %
63.33%
Holding
107
New
9
Increased
18
Reduced
18
Closed
14
Top Buys
| 1 |
BioNTech
BNTX
|
$89M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$34.6M |
| 3 |
argenx
ARGX
|
$24.1M |
| 4 |
PayPal
PYPL
|
$21.6M |
| 5 |
EPZM
Epizyme, Inc
EPZM
|
$18.5M |
Top Sells
| 1 |
MDCO
Medicines Co
MDCO
|
$70M |
| 2 |
NVIDIA
NVDA
|
$34.8M |
| 3 |
Avantor
AVTR
|
$22.7M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$17M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$16M |
Sector Composition
| 1 | Healthcare | 68.01% |
| 2 | Consumer Discretionary | 27.76% |
| 3 | Communication Services | 1.58% |
| 4 | Technology | 1.29% |
| 5 | Financials | 0.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
FibroGen
FGEN
$47.8M
| $17.2M | 0.66% | 400,000 +220,000 | +122% | +$9.44M |
|
27
StoneCo
STNE
$4.41B
| $16M | 0.62% | 400,000 +100,000 | +33% | +$3.99M |
|
|
DCPH
28
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $15.6M | 0.6% | 250,000 -250,000 | -50% | -$15.6M |
|
29
Uber
UBER
$196B
| $14.9M | 0.57% | 500,000 | – | – |
|
30
Ascendis Pharma
ASND
$11.8B
| $13.9M | 0.54% | 100,000 -50,000 | -33% | -$6.96M |
|
31
Iovance Biotherapeutics
IOVA
$807M
| $13.8M | 0.53% | 500,000 -200,000 | -29% | -$5.54M |
|
|
TCDA
32
DELISTED
Tricida, Inc. Common Stock
TCDA
| $13.6M | 0.52% | 360,000 | – | – |
|
|
SWTX
33
DELISTED
SpringWorks Therapeutics
SWTX
| $13.5M | 0.52% | 350,000 +41,474 | +13% | +$1.6M |
|
34
ProQR Therapeutics
PRQR
$237M
| $12.9M | 0.5% | 1,300,000 | – | – |
|
|
HARP
35
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $12.6M | 0.49% | +850,000 | New | +$12.6M |
|
36
Y-mAbs Therapeutics
YMAB
$388M
| $12.5M | 0.48% | 400,000 | – | – |
|
|
HOOK
37
DELISTED
HOOKIPA Pharma
HOOK
| $12.3M | 0.47% | 1,004,987 -129,629 | -11% | -$1.59M |
|
|
ALBO
38
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $11.4M | 0.44% | 450,200 | – | – |
|
|
DRNA
39
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $11M | 0.43% | 500,000 -500,000 | -50% | -$11M |
|
|
SAGE
40
DELISTED
Sage Therapeutics
SAGE
| $10.8M | 0.42% | 150,000 | – | – |
|
|
CLVS
41
DELISTED
Clovis Oncology, Inc.
CLVS
| $10.4M | 0.4% | 1,000,000 +500,000 | +100% | +$5.21M |
|
|
RETA
42
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $10.2M | 0.39% | +50,000 | New | +$10.2M |
|
|
AGEN
43
Agenus
AGEN
$133M
| $10.2M | 0.39% | 2,500,000 | – | – |
|
|
AXDX
44
DELISTED
Accelerate Diagnostics
AXDX
| $10.1M | 0.39% | 600,000 +100,000 | +20% | +$1.69M |
|
|
BLUE
45
DELISTED
bluebird bio
BLUE
| $8.78M | 0.34% | 100,000 | – | – |
|
46
Replimune Group
REPL
$422M
| $8.61M | 0.33% | 600,000 | – | – |
|
47
AC Immune
ACIU
$205M
| $8.52M | 0.33% | 1,000,000 | – | – |
|
48
Cartesian Therapeutics
RNAC
$261M
| $8.12M | 0.31% | 3,413,629 +1,313,629 | +63% | +$3.13M |
|
49
Solid Biosciences
SLDB
$427M
| $8.01M | 0.31% | 1,800,000 +100,000 | +6% | +$445K |
|
50
TG Therapeutics
TGTX
$4.65B
| $7.22M | 0.28% | 650,000 -250,000 | -28% | -$2.78M |
|